Thalidomide-O-C3-NH2 is primarily utilized in the development of new pharmaceutical compounds due to its modified structure, which enhances its potential therapeutic properties. It is often explored in cancer research, particularly in the treatment of multiple myeloma and other malignancies, where it can act as an immunomodulatory agent. The compound's ability to inhibit angiogenesis makes it valuable in preventing the growth of blood vessels that supply tumors, thereby limiting their progression. Additionally, it is studied for its anti-inflammatory effects, which could be beneficial in treating conditions like Crohn's disease and lupus. Researchers also investigate its potential in neurodegenerative diseases, as it may help regulate immune responses and reduce inflammation in the central nervous system. Its modified structure allows for improved targeting and reduced side effects compared to its parent molecule, thalidomide.